Silencing SATB1 inhibits the malignant phenotype and increases sensitivity of human osteosarcoma U2OS cells to arsenic trioxide

International Journal of Medical Sciences

Volumn 11, Issue 12, 2014, Pages 1262-1269

  Zhang, Haiying ^a   Su, Xuejin ^a   Guo, Li ^b   Zhong, Lingzhi ^a   Li, Wenxue ^a   Yue, Zhen ^a   Wang, Xiaotong ^a   Mu, Yan ^a   Li, Xinna ^a   Li, Ronggui ^a   Wang, Zonggui ^c  

^a Basic Medical College   (China)

^b JILIN UNIVERSITY   (China)

^c THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenic trioxide; Invasion; Migration; SATB1

Indexed keywords

ARSENIC TRIOXIDE; BINDING PROTEIN; MESSENGER RNA; SHORT HAIRPIN RNA; SPECIAL AT RICH BINDING PROTEIN 1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MATRIX ATTACHMENT REGION BINDING PROTEIN; ORGANOARSENIC DERIVATIVE; OXIDE; RNA; SATB1 PROTEIN, HUMAN; SMALL INTERFERING RNA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL ASSAY; CELL MIGRATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NICK END LABELING; NUCLEOTIDE SEQUENCE; PHENOTYPE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SATB1 GENE; TUMOR INVASION; U2OS CELL LINE; ANTAGONISTS AND INHIBITORS; BONE NEOPLASMS; CELL MOTION; DRUG RESISTANCE; GENE EXPRESSION; GENETICS; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; ARSENICALS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MATRIX ATTACHMENT REGION BINDING PROTEINS; NEOPLASM INVASIVENESS; OSTEOSARCOMA; OXIDES; PHENOTYPE; RNA, MESSENGER; RNA, NEOPLASM; RNA, SMALL INTERFERING;

EID: 84907881975     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.10038     Document Type: Article

References (36)

1. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res. 2010; 5: 78-87.
2. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004; 9: 422-41.
3. Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol. 2007; 19: 341-6.
4. Pakos EE, Nearchou AD, Grimer RJ, Koumoullis HD, Abudu A, Bramer JA, et al. Prognostic factors and outcomes for osteosarcoma: an international collaboration. Eur J Cancer. 2009; 45: 2367-75.
5. Emadi A, Gore SD. Arsenic trioxide - An old drug rediscovered. Blood Rev. 2010; 24: 191-9.
6. Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369: 111-21.
7. Mayor S. Arsenic trioxide combination improves survival in APL. Lancet Oncol. 2013; 14: e346.
8. Mi JQ, Li JM, Shen ZX, Chen SJ, Chen Z. How to manage acute promyelocytic leukemia. Leukemia. 2012; 26: 1743-51.
9. Chow SK, Chan JY, Fung KP. Inhibition of cell proliferation and the action mechanisms of arsenic trioxide (As2O3) on human breast cancer cells. J Cell Biochem. 2004; 93: 173-87.
10. Mann KK, Wallner B, Lossos IS, Miller WH, Jr. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs. 2009; 18: 1727-34.
11. Li Y, Qu X, Qu J, Zhang Y, Liu J, Teng Y, et al. Arsenic trioxide induces apoptosis and G2/M phase arrest by inducing Cbl to inhibit PI3K/Akt signaling and thereby regulate p53 activation. Cancer Lett. 2009; 284: 208-15.
12. Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y, et al. Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J Biol Chem. 2008; 283: 18969-79.
13. Fei M, Lu M, Wang Y, Zhao Y, He S, Gao S, et al. Arsenic trioxide-induced growth arrest of human hepatocellular carcinoma cells involving FOXO3a expression and localization. Med Oncol. 2009; 26: 178-85.
14. Zhang S, Guo W, Ren TT, Lu XC, Tang GQ, Zhao FL. Arsenic trioxide inhibits Ewing's sarcoma cell invasiveness by targeting p38(MAPK) and c-Jun N-terminal kinase. Anticancer Drugs. 2012; 23: 108-18.
15. Dickinson LA, Joh T, Kohwi Y, Kohwi-Shigematsu T. A tissue-specific MAR/SAR DNA-binding protein with unusual binding site recognition. Cell. 1992; 70: 631-45.
16. Tattermusch A, Brockdorff N. A scaffold for X chromosome inactivation. Hum Genet. 2011; 130: 247-53.
17. Shannon MF. A nuclear address with influence. Nat Genet. 2003; 34: 4-6.
18. Cai S, Han HJ, Kohwi-Shigematsu T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat Genet. 2003; 34: 42-51.
19. Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008; 452: 187-93.
20. Zheng J. Is SATB1 a master regulator in breast cancer growth and metastasis? Womens Health (Lond Engl). 2008; 4: 329-32.
21. Li QQ, Chen ZQ, Xu JD, Cao XX, Chen Q, Liu XP, et al. Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci. 2010; 101: 80-6.
22. Cheng C, Lu X, Wang G, Zheng L, Shu X, Zhu S, et al. Expression of SATB1 and heparanase in gastric cancer and its relationship to clinicopathologic features. APMIS. 2010; 118: 855-63.
23. Zhang H, Qu S, Li S, Wang Y, Li Y, Wang Y, et al. Silencing SATB1 inhibits proliferation of human osteosarcoma U2OS cells. Mol Cell Biochem. 2013; 378: 39-45.
24. Wang Y, Wei Y, Zhang H, Shi Y, Li Y, Li R. Arsenic trioxide induces apoptosis of p53 null osteosarcoma MG63 cells through the inhibition of catalase. Med Oncol. 2012; 29: 1328-34.
25. Yedjou CG, Moore P, Tchounwou PB. Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment. Int J Environ Res Public Health. 2006; 3: 136-40.
26. Huan SY, Yang CH, Chen YC. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy. Leuk Lymphoma. 2000; 38: 283-93.
27. Mohseny AB, Machado I, Cai Y, Schaefer KL, Serra M, Hogendoorn PC, et al. Functional characterization of osteosarcoma cell lines provides representative models to study the human disease. Lab Invest. 2011; 91: 1195-205.
28. Guo W, Tang XD, Tang S, Yang Y. [Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma]. Zhonghua Wai Ke Za Zhi. 2006; 44: 805-8.
29. Lakshminarayana Reddy CN, Vyjayanti VN, Notani D, Galande S, Kotamraju S. Down-regulation of the global regulator SATB1 by statins in COLO205 colon cancer cells. Mol Med Rep. 2010; 3: 857-61. doi:10.3892/mmr.2010.338.
30. Entschladen F, Drell TL, Lang K, Joseph J, Zaenker KS. Tumour-cell migration, invasion, and metastasis: navigation by neurotransmitters. Lancet Oncol. 2004; 5: 254-8.
31. Meng WJ, Yan H, Zhou B, Zhang W, Kong XH, Wang R, et al. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int J Colorectal Dis. 2011; 27: 143-50.
32. Tu W, Luo M, Wang Z, Yan W, Xia Y, Deng H, et al. Upregulation of SATB1 promotes tumor growth and metastasis in liver cancer. Liver Int. 2012; 32: 1064-78.
33. Chu SH, Ma YB, Feng DF, Zhang H, Zhu ZA, Li ZQ, et al. Upregulation of SATB1 is associated with the development and progression of glioma. J Transl Med. 2012; 10: 149-52.
34. Chu SH, Ma YB, Feng DF, Li ZQ, Jiang PC. Correlation between SATB1 and Bcl-2 expression in human glioblastoma multiforme. Mol Med Rep. 2013; 7: 139-43.
35. Gong F, Sun L, Wang Z, Shi J, Li W, Wang S, et al. The BCL2 gene is regulated by a special AT-rich sequence binding protein 1-mediated long range chromosomal interaction between the promoter and the distal element located within the 3'-UTR. Nucleic Acids Res. 2011; 39: 4640-52. doi:10.1093/nar/gkr023.
36. Endo K, Shackelford J, Aga M, Yoshizaki T, Pagano JS. Upregulation of special AT-rich-binding protein 1 by Epstein-Barr virus latent membrane protein 1 in human nasopharyngeal cells and nasopharyngeal cancer. J Gen Virol. 2013; 94: 507-13. doi:10.1099/vir.0.046243-0.